



## **Shilpa Medicare Limited**

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Dated: 14 May 2024

To,  
Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**Mumbai-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**  
**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

---

### **Clinical trial Announcement for SML 007**

Shilpa Medicare Ltd announces the successful completion of early clinical development and ongoing Phase 3 clinical trial of its newly developed drug “SML-007”, for the treatment of non-alcoholic fatty liver disease (NAFLD). The recruitment of NAFLD patients (Fibrosis stage F2 & F3) for Phase 3 trial has been completed across multiple centres. Phase 3 clinical study dosing is expected to be completed by end of Q 1 and study is likely to be concluded by end of Q 2 of current fiscal year.

SML 007 is an orally administered drug with significant benefits over the currently available bile acid family of drugs used for the treatment of liver diseases. These additional benefits are reshaping bile acid synthesis, thereby promoting the restoration of liver FXR signalling and also action through adiponectin receptor pathway. SML-007 has demonstrated superior anti-inflammatory and antifibrotic effect in pre-clinical studies. SML-007 demonstrates improvement of fibrosis.

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting about twenty five percent of the global population. About fourteen percent of persons with NAFLD have a more aggressive form known as non-alcoholic steatohepatitis (NASH), which can progress to advanced liver fibrosis, cirrhosis, or liver cancer.

**With Regards**

**For SHILPA MEDICARE LIMITED**

**Ritu Tiwary**  
Digitally signed by Ritu  
Tiwary  
Date: 2024.05.14  
20:05:48 +05'30'

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**